Berlin, 22.10.2018 – 270. Stellungnahme der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) e. V. in der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) e. V. zum Thema Pertuzumab (Mammakarzinom) – Nutzenbewertung gemäß § 35a SGB V

doi:10.1055/a-0852-5446

Geburtshilfe und Frauenheilkunde, Table of Contents

Geburtshilfe Frauenheilkd 2019; 79(04): 344-350
DOI: 10.1055/a-0852-5446

DGGG

Georg Thieme Verlag KG Stuttgart · New York

Berlin, 22.10.2018 – 270. Stellungnahme der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) e. V. in der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) e. V. zum Thema Pertuzumab (Mammakarzinom) – Nutzenbewertung gemäß § 35a SGB V

Abstract

Full Text

References

Literatur
1 Curigliano G, Burstein HJ, Winer EP. et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017; 28: 1700-1712 doi:10.1093/annonc/mdx308
2 Henry NL, Somerfield MR, Abramson VG. et al. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations. J Clin Oncol 2016; 34: 2303-2311 doi:10.1200/JCO.2015.65.8609
3 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms. Version 4.1, 2018 AWMF Registernummer: 032-045OL. Online: http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/ Stand: 19.03.2019
4 Moja L, Tagliabue L, Balduzzi S. et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 2012; (04) CD006243
5 Romond EH, Perez EA, Bryant J. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684 doi:10.1056/NEJMoa052122
6 Slamon D, Eiermann W, Robert N. et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365: 1273-1283 doi:10.1056/NEJMoa0910383
7 Au H, Eiermann W, Robert NJ. et al. Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study. Oncologist 2013; 18: 812-818 doi:10.1634/theoncologist.2013-0091
8 Baselga J, Cortes J, Kim S. et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-119 doi:10.1056/NEJMoa1113216
9 Gianni L, Pienkowski T, Im Y. et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25-32 doi:10.1016/S1470-2045(11)70336-9
10 Fasching PA, Hartkopf AD, Gass P. et al. Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis. Breast Cancer Res Treat 2018;
11 von Minckwitz G, Procter M, de Azambuja E. et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med 2017; 377: 122-131 doi:10.1056/NEJMoa1703643
12 Piccart-Gebhart MJ, Procter M, Leyland-Jones B. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672 doi:10.1056/NEJMoa052306
13 Smith I, Procter M, Gelber RD. et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369: 29-36 doi:10.1016/S0140-6736(07)60028-2
14 Cherny NI, Sullivan R, Dafni U. et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015; 26: 1547-1573 doi:10.1093/annonc/mdv249
15 Mayer EL. Early and late long-term effects of adjuvant chemotherapy. Am Soc Clin Oncol Educ Book 2013;
16 Okuyama H, Nakamura S, Akashi-Tanaka S. et al. QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer. Eur J Breast Health 2018; 14: 194-198 doi:10.5152/ejbh.2018.4174
17 Tao JJ, Visvanathan K, Wolff AC. Long term side effects of adjuvant chemotherapy in patients with early breast cancer. Breast 2015; 24 (Suppl. 02) S149-S153 doi:10.1016/j.breast.2015.07.035
18 Bouchardy C, Rapiti E, Blagojevic S. et al. Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol 2007; 25: 1858-1869 doi:10.1200/JCO.2006.10.4208
19 Giordano SH, Hortobagyi GN, Kau SC. et al. Breast cancer treatment guidelines in older women. J Clin Oncol 2005; 23: 783-791 doi:10.1200/JCO.2005.04.175
20 Enger SM, Thwin SS, Buist DSM. et al. Breast cancer treatment of older women in integrated health care settings. J Clin Oncol 2006; 24: 4377-4383 doi:10.1200/JCO.2006.06.3065
21 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Pertuzumab (Mammakarzinom) – Nutzenbewertung gemäß § 35a SGB V. Dossierbewertung A18-41. Version 1.0; 27.09.2018. Online: https://www.iqwig.de/de/projekte-ergebnisse/projekte/arzneimittelbewertung/2018/a18-41-pertuzumab-mammakarzinom-nutzenbewertung-gemaess-35a-sgb-v.10102.html Stand: 15.10.2018